New Schering chief has plans for imaging agents:
This article was originally published in Clinica
The incoming chairman of the executive board at German company Schering pharmaceuticals company promised that it would leverage its brand leading position in radiopharmaceuticals. Dr Hubertus Erlen takes over from Dr Giuseppe Vita, who retires after 12 years as chairman. Schering's R&D strategy is to use carrier molecules used in diagnostic imaging to destroy cancer cells.
You may also be interested in...
Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.
The economic stress on payers caused by the pandemic will cause a setback in the development of payment approaches for regenerative therapy, Blue Cross Blue Shield executive warns.
An interim final rule posted by the CMS this week widens further a series of telehealth exemptions and lab specimen collection payment provisions it has previously issued to help providers during the COVID-19 pandemic.